Why Is CORCEPT THERAPEUTICS (CORT) Stock Up Today?

CORT stock surged 29.03% to $119.93 on July 30, driven by a combination of a strong earnings report, an upgraded price target, and positive corporate updates. The stock opened with a 21.3% gap up from the previous close and continued to climb throughout the session, reaching a high of $120.73. The move followed the release of second-quarter financial results and a corporate update that included a revenue guidance increase and progress in key product launches.

What Happened

Corcept Therapeutics reported second-quarter results and provided a corporate update that highlighted strong financial performance and key milestones in its pipeline. The company raised its 2026 revenue guidance to a range of $1.1 billion to $1.2 billion, reflecting the continued success of its Lifyorli launch, which now includes 1,300 patients. Additionally, the drug relacorilant is awaiting a December 17 PDUFA decision, which could lead to regulatory approval. The company filed a Form 8-K to disclose these results and other operational updates.

H.C. Wainwright responded to the developments by raising its price target for CORT to $165, maintaining a Buy rating. This upgrade contributed to the stock’s sharp intraday move. The stock’s premarket momentum was also reflected in broader market reports, with Corcept Therapeutics being cited as a top performer in the health care sector.

What The Data Shows

The stock opened at $112.72, a 21.3% gap from the prior close of $92.95. It traded as high as $120.73 before settling at $120.03 in the final minutes of the session. Trading volume reached 1.1 million shares, which is 0.8 times the 3-month daily average. The stock has traded within a 52-week range of $28.66 to $97.63, and its price trend over the last eight sessions was a modest gain of 1.5%. Over the past 90 days, insiders have sold 13 times, totaling $26.3 million, with no insider purchases reported.

What To Watch

The company’s next key event is the December 17 PDUFA date for relacorilant, which could significantly impact its growth trajectory. Investors should also monitor the breadth of analyst coverage and any further developments in the drug approval process.